https://orcid.org/0000-0002-8389-0701
References
- Travis WD. Classification of lung cancer. Semin Roentgenol. 2011;46:178–186.
- Noronha V, Dikshit R, Raut N, et al. Epidemiology of lung cancer in India: focus on the differences between non-smokers and smokers: a single-center experience. Indian J Cancer. 2012;49:74.
- Osterlind K, Hansen HH, Hansen M, et al. Mortality and morbidity in long-term surviving patients treated with chemotherapy with or without irradiation for small-cell lung cancer. J Clin Oncol. 1986;4:1044–1052.
- Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers—a different disease. Nat Rev Cancer. 2007;2007:778–790.
- Lewis SJ, Cherry NM, Niven RM, et al. GSTM1, GSTT1 and GSTP1 polymorphisms and lung cancer risk. Cancer Lett. 2002;180:165–171.
- McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene. 2006;25:1639–1648.
- Abbas M, Kushwaha VS, Srivastava K, et al. Impact of GSTM1, GSTT1 and GSTP1 genes polymorphisms on clinical toxicities and response to concomitant chemoradiotherapy in cervical cancer. Br J Biomed Sci. 2018;75:169–174.
- Xiao HL, Yang ZT, Han F, et al. Association of glutathione S-transferase (GST) genetic polymorphisms with treatment outcome of cisplatin-based chemotherapy for advanced non-small cell lung cancer in a Chinese population. Genet Mol Res. 2016;15:1–7.
- Field JK, Liloglou T, Xinarianos G, et al. Genetic alterations in bronchial lavage as a potential marker for individuals with a high risk of developing lung cancer. Cancer Res. 1999;59:2690–2695.
- To-Figueras J, Gene M, Gomez-Catalan J, et al. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) polymorphisms and lung cancer risk among Northwestern Mediterraneans. Carcinogenesis. 1997;18:1529–1533.
- Goto I, Yoneda S, Yamamoto M, et al. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res. 1996;56:3725–3730.
- Liu K, Lin Q, Ding H, et al. Predictive potential role of GSTs gene polymorphisms in the treatment outcome of advanced non-small cell lung cancer patients. Int J Clin Exp Med. 2015;8:20918.
- Jia W, Sun JY, Jia KY, et al. Role of GSTM1, GSTT1, and GSTP1 IIe105Val gene polymorphisms in the response to chemotherapy and overall survival of advanced non-small cell lung cancer. Genet Mol Res. 2016;15.
- Yang Y, Xian L. The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis. Tumour Biol. 2014;35:6791–6799.
- Li W, Yue W, Zhang L, et al. Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients. Lung. 2012;190:91–98.